In an interview with The Pharma Letter, Nicholas Saccomano, chief science officer of Array BioPharma, discusses its lead product filanesib, its partnerships wit 15 July 2014
The record start to 2014’s pharma M&A has been a welcome boost to a deal market that had been in the doldrums, writes Gordon Hamilton, partner and Head of Healt 28 May 2014
In an interview with The Pharma Letter, Egalet Corporation’s chief executive Bob Radie discusses the company’s lead product Egalet-001, its proprietary technolo 11 April 2014
The spotlight was on the European uptake of biosimilars at the European Generic medicines Association’s (EGA) 12th annual conference on biosimilar medicines in 7 April 2014
As health care budgets are squeezed worldwide and access issues continue to make the headlines, the price of a new drug has never been more important. The Pharm 20 March 2014
In an interview with The Pharma Letter, CEO Michael Forer discusses ADC Therapeutics' developing pipeline and intentions to take multiple proprietary ADCs into 19 March 2014
The Pharma Letter interviewed chief executive Darren Kelly about Fibrotech’s ethos and its lead product, FT011, an antifibrotic to prevent the tissue fibrosis a 18 March 2014
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.